
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 836 | 810 | 980 | - | - | - |
Fund Return | -16.43% | -18.97% | -2.04% | - | - | - |
Place in category | 88 | 84 | 84 | - | - | - |
% in Category | 92 | 96 | 96 | - | - | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
INF966L01689 | 228.32B | -17.06 | 21.72 | 18.72 | ||
INF966L01051 | 228.32B | -17.19 | 20.32 | 17.88 | ||
Quant Mid Cap Fund Growth | 76.16B | -14.99 | 18.20 | 15.54 | ||
INF966L01887 | 76.16B | -14.83 | 20.05 | 16.76 | ||
Quant Consumption Fund Growth | 61.89B | -12.49 | 16.01 | 16.93 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Reliance Pharma Fund - Bonus | 76.37B | -14.28 | 17.38 | 13.51 | ||
Reliance Pharma Dividend Payout | 76.37B | -14.99 | 16.77 | 14.45 | ||
Reliance Pharma Fund - Growth | 76.37B | -14.28 | 17.38 | 13.51 | ||
Reliance Pharma Direct Bonus | 76.37B | -14.16 | 18.44 | 14.52 | ||
Reliance Pharma Direct Growth | 76.37B | -14.16 | 18.44 | 14.52 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Divi's Labs | INE361B01024 | 9.67 | 5,240.25 | -4.42% | |
RPG Life Sciences Limited | INE105J01010 | 9.05 | 1,998.55 | -8.15% | |
Aster DM Healthcare | INE914M01019 | 8.18 | 475.95 | -1.36% | |
Zydus Lifesciences | INE010B01027 | 7.39 | 837.10 | -3.44% | |
Ipca Laboratories | INE571A01038 | 7.13 | 1,299.40 | -7.14% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Sell | Neutral |
Technical Indicators | Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review